Jump to content

FBXO32

From Wikipedia, the free encyclopedia
(Redirected from FBXO32 (gene))
FBXO32
Identifiers
AliasesFBXO32, Fbx32, MAFbx, F-box protein 32
External IDsOMIM: 606604; MGI: 1914981; HomoloGene: 12182; GeneCards: FBXO32; OMA:FBXO32 - orthologs
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_148177
NM_001242463
NM_058229

NM_026346

RefSeq (protein)

NP_001229392
NP_478136
NP_680482

NP_080622

Location (UCSC)Chr 8: 123.5 – 123.54 MbChr 15: 58.04 – 58.08 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

F-box only protein 32, also known as "MAFbx", for "Muscle Atrophy F-box gene", and "Atrogin-1," is a protein that in humans is encoded by the FBXO32 gene.[5][6][7]

Function

[edit]

This gene encodes a member of the F-box protein family which is characterized by an approximately 40 amino acid motif, the F-box. The F-box proteins constitute one of the four subunits of the ubiquitin protein ligase complex called SCFs (SKP1-cullin-F-box), which function in phosphorylation-dependent ubiquitination. The F-box proteins are divided into 3 classes: Fbws containing WD-40 domains, Fbls containing leucine-rich repeats, and Fbxs containing either different protein-protein interaction modules or no recognizable motifs. The protein encoded by this gene belongs to the Fbxs class and contains an F-box domain. This protein is highly expressed during muscle atrophy, whereas mice deficient in this gene were found to be resistant to atrophy. This protein is thus a potential drug target for the treatment of muscle atrophy. Alternative splicing of this gene results in two transcript variants encoding two isoforms of different sizes.[7]

Interactions

[edit]

FBXO32 has been shown to interact with EIF3A.[8]

Cancer

[edit]

FBXO32 gene has been observed progressively downregulated in Human papillomavirus-positive neoplastic keratinocytes derived from uterine cervical preneoplastic lesions at different levels of malignancy.[9] For this reason, FBXO32 is likely to be associated with tumorigenesis and may be a potential prognostic marker for uterine cervical preneoplastic lesions progression.[9]

References

[edit]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000156804Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000022358Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuela DM, DeChiara TM, Stitt TN, Yancopoulos GD, Glass DJ (Nov 2001). "Identification of ubiquitin ligases required for skeletal muscle atrophy". Science. 294 (5547): 1704–8. Bibcode:2001Sci...294.1704B. doi:10.1126/science.1065874. PMID 11679633. S2CID 37349291.
  6. ^ Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL (Dec 2001). "Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy". Proc. Natl. Acad. Sci. U.S.A. 98 (25): 14440–5. Bibcode:2001PNAS...9814440G. doi:10.1073/pnas.251541198. PMC 64700. PMID 11717410.
  7. ^ a b "Entrez Gene: FBXO32 F-box protein 32".
  8. ^ Lagirand-Cantaloube J, Offner N, Csibi A, Leibovitch MP, Batonnet-Pichon S, Tintignac LA, Segura CT, Leibovitch SA (Apr 2008). "The initiation factor eIF3-f is a major target for atrogin1/MAFbx function in skeletal muscle atrophy". EMBO J. 27 (8): 1266–76. doi:10.1038/emboj.2008.52. PMC 2367397. PMID 18354498.
  9. ^ a b Rotondo JC, Bosi S, Bassi C, Ferracin M, Lanza G, Gafà R, Magri E, Selvatici R, Torresani S, Marci R, Garutti P, Negrini M, Tognon M, Martini F (April 2015). "Gene expression changes in progression of cervical neoplasia revealed by microarray analysis of cervical neoplastic keratinocytes". J Cell Physiol. 230 (4): 802–812. doi:10.1002/jcp.24808. hdl:11392/2066612. PMID 25205602. S2CID 24986454.

Further reading

[edit]